Staphylococcus lugdunensis
Background
- Staphylococcus lugdunensis is a coagulase-negative staphylococcus with unusual pathogenicity resembling that of S. aureus[1]
- A Gram Positive Bacteria
- Causes endocarditis, meningitis, and Skin and Soft Tissue Infections
Antibiotic susceptibility pattern of 540 Staphylococcus lugdunensis isolates tested with the disc diffusion method:[2]
| Antibiotic | No. (%) susceptible |
|---|---|
| Penicillin G | 403 (74.6) |
| Gentamicin | 538 (99.6) |
| Rifampicin | 538 (99.6) |
| Cefoxitin | 538 (99.6) |
| Fusidic acid | 528 (97.8) |
| Trimethoprim/sulfamethoxazole | 539 (99.8) |
| Norfloxacin | 539 (99.8) |
| Clindamycin | 494 (91.5) |
| Erythromycin | 506 (93.7) |
Antibiotic Sensitivities[3]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
Table Overview
See Also
- Microbiology (Main)
- Staphylococcus Species
References
- Taha L, Stegger M, and Soderquist B. Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options, European Journal of Clinical Microbiology & Infectious Diseases, May 2019. Accessed 21 December 2020.
- Taha L, Stegger M, and Soderquist B. Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options, European Journal of Clinical Microbiology & Infectious Diseases, May 2019. Accessed 21 December 2020.
- Sanford Guide to Antimicrobial Therapy 2010
This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.